Regenxbio Share Surge 20% on Duchenne Muscular Dystrophy Treatment Trial Data, Expansion
Regenxbio shares surged 20% after disclosing new, positive efficacy and safety data of its Duchenne muscular dystrophy treatment. Shares were recently trading around $11.55. The stock is down 46% on the year.
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price ...
Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...
Regenxbio’s investigational gene therapy improved muscle function for patients with Duchenne muscular dystrophy (DMD) in a phase 1/2 study. | Regenxbio’s investigational gene therapy improved muscle ...
Analyst Gena Wang from Barclays maintained a Buy rating on RegenXBio (RGNX – Research Report) and keeping the price target at $50.00.Don't Miss ...
REGENXBIO Inc. (Nasdaq: RGNX) today announced that AFFINITY DUCHENNE®, the multi-center, open-label trial of RGX-202, a ...
REGENXBIO stock is trading higher on Monday after the company reached a critical point in its trial for Duchenne gene therapy.
This was corrected on 11/16/2024 at 5:43 PM. An earlier version of this article mistakenly said that RGX-202 uses the AAV9 vector. It uses the AAV8 vector. The article has also been clarified to ...
REGENXBIO is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic ...
These factors have contributed to increasing the probability of success for RGX-202 and raising the price target, affirming the Buy rating recommendation. According to TipRanks, Foroohar is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback